PHAR — Pharming Group N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1828316 ·
Last close
$11.46
Market Cap
$811.12M
52W High
$14.79
52W Low
$9.62
ADV30
18,127
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 90,213,000 | 75,668,000 | -111,000 | 1,638,000 | 467,984,000 | 158,281,000 | 197,494,000 |
| Mar 2026 | 72,447,000 | 65,803,000 | -5,288,000 | -5,213,000 | 489,365,000 | 52,379,000 | 220,405,000 |
| Dec 2025 | 106,500,000,000 | 85,400,000,000 | 2,000,000,000 | 5,300,000,000 | 499,963,000 | 145,305,000 | 222,861,000 |
| Sep 2025 | 97,287,000 | 90,216,000 | 15,751,000 | 7,548,000 | 473,785,000 | 132,370,000 | 209,141,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$35,027,000
Investing CF
$-85,236,000
Financing CF
$-697,000
CapEx
$-660,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-278,245,000
Inventory
$65,428,000
Receivables
$56,980,000
ST Investments
$0
EBIT TTM
$30,561,000
Pretax Income TTM
$15,844,000
Interest Exp TTM
$14,717,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$366,479,008
EBITDA
$32,879,000
Free Cash Flow
$37,686,124
Enterprise Value
$793,734,784
Total Cash
$158,280,992
Total Debt
$113,295,000
Shares Out
70,778,124
Trailing EPS
$0.14
Book Value
$3.82
ROE
3.6%
ROA
3.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 376,134,000 | 20,881,000 | 2,851,000 | 499,963,000 | 222,861,000 | — | 54,708,000 |
| Dec 2024 | 297,200,000 | -3,665,000 | -11,841,000 | 399,985,000 | 178,924,000 | — | -1,795,000 |
| Dec 2023 | 245,316,000 | -22,289,000 | -10,548,000 | 462,854,000 | 244,073,000 | — | -17,302,000 |
| Dec 2022 | 205,622,000 | 9,860,000 | 13,674,000 | 425,797,000 | 221,159,000 | — | 22,458,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLN | Silence Therapeutics plc | $826.03M | $13.29 | — |
| CYRX | Cryoport, Inc. | $827.61M | $16.34 | — |
| NGNE | Neurogene Inc. | $793.25M | $39.64 | — |
| STTK | Shattuck Labs, Inc. | $792.87M | $7.90 | — |
| ANL | Adlai Nortye Ltd. | $831.68M | $14.16 | — |
News headlines (Yahoo Finance, 1h cache)
Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ...
2026-07-30 19:04 · Yahoo
Form 8.3
2026-08-14 10:36 · Yahoo
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
2026-08-13 05:00 · Yahoo
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
2026-08-04 06:00 · Yahoo
Pharming Group (ENXTAM:PHARM) Could Be 63% Undervalued After Guidance Cut And Half Year Results
2026-08-03 00:15 · Yahoo
Pharming Group Q2 Earnings Call Highlights
2026-07-30 13:04 · Yahoo
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
2026-07-30 05:00 · Yahoo
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
2026-07-16 06:00 · Yahoo
Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case
2026-06-27 13:08 · Yahoo
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
2026-06-15 11:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.